Home › Trials › NCT06261047
Clinical trial No longer in our active list Observational Ages 18 to 75

Radiotherapy for patients with advanced liver cancer

Official title: Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer: a Multicenter, Single-arm, Phase II Clinical Trial.

Run by Shandong Cancer Hospital and Institute · NCT06261047 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study tests if adding radiotherapy can help people with advanced liver cancer delay the need for more aggressive drug treatments after their initial therapy.

Quick facts

Study typeObservational
Ages18 Years to 75 Years
SexAll
Enrollment36 (estimated)
SponsorShandong Cancer Hospital and Institute
Academic / other
Drugs / interventionsramucirumab, atezolizumab, bevacizumab, lenvatinib, cabozantinib, immunotherapy
Locations1 site (Jinan, Shandong)
Trial IDNCT06261047 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 75 with oligometastatic HCC and stable disease after systemic therapy.

Probably not a fit

Patients with other malignancies or those with poor liver function may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the impact of radiotherapy on patients with oligoprogressive hepatocellular carcinoma (HCC) who have previously undergone systemic therapy. It aims to evaluate how radiotherapy can delay the need for second-line drug therapy in this patient population. The study includes patients with a specific staging of HCC and assesses their liver function and overall health status. By combining radiotherapy with existing treatment strategies, the study seeks to improve patient outcomes in a challenging treatment landscape.

Why it matters

Potential benefit: If successful, this approach could extend the time before patients need to switch to second-line therapies, potentially improving their quality of life.

How similar studies have gone: While the combination of radiotherapy and immunotherapy has shown promise in other studies, this specific approach in oligoprogressive HCC is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Obtain written informed consent before implementing any trial-related procedures.
* Male or female, aged 18 years or older, and 75 years or younger.
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.
* Histological or cytological confirmation of primary hepatocellular carcinoma (HCC), or diagnosed according to the Clinical Diagnosis and Treatment Guidelines for Primary - Liver Cancer (2019 edition) issued by the National Health Commission of the People's Republic of China.
* Tumor staged as BCLC stage C; patients have ≤5 lesions (≤3 affected organs) with oligometastasis or oligoprogression.
* Liver function assessed by Child-Pugh score ≤7 points.
* Availability of tumor samples for biomarker assessment.
* Stable disease with systemic therapy for ≥3 months and an anticipated survival period of ≥6 months.

Exclusion Criteria:

* Diagnosis of malignancy other than liver cancer within 3 years before enrollment (excluding curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, and/or in situ carcinoma).
* Currently participating in interventional clinical research treatment, or received other investigational drugs or investigational device therapy within the past 4 weeks before enrollment.
* Received traditional Chinese medicine or immunomodulatory drugs with anti-tumor indications within 2 weeks before enrollment (including thymosin, interferon, interleukin, except for local use to control pleural effusion).
* Experienced active autoimmune diseases requiring systemic treatment (such as disease-modifying drugs, corticosteroids, or immunosuppressive agents) within 2 years before enrollment. Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered systemic treatment.
* Received radiotherapy within 2 weeks before enrollment.
* HIV +
* Active untreated hepatitis B (defined as HBsAg positive with HBV-DNA copy number exceeding the upper limit of normal value in the laboratory of the participating center).
* Pregnant or lactating women.

Where it's running

  • Jinbo Yue
    Jinan, Shandong, China     Recruiting

Study contacts

  • Principal investigator: jibo yue, dorctor — Shandong Cancer Hospital and Institute
  • Study coordinator: jinbo yue, dorctor
  • Email: yuejinbo@hotmail.com
  • Phone: +86053167626442

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Hepatocellular Carcinoma 412Radiotherapy 309Shandong Cancer Hospital and Institute 38
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.